Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131539) titled 'A Single-Arm, Exploratory Study of Ipalolito Vorelizumab as Adjuvant Therapy in Patients with High-Risk Hepatocellular Carcinoma Following Resection' on Sept. 3.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Shandong Provincial Hospital
Condition:
Patients with hepatocellular carcinoma at high risk of recurrence after resection
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-03
Target Sample Size: Experimental Group:32;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=339925
Disclaimer: Cu...